Thymoglobulin, sirolimus, and reduced-dose cyclosporine provides excellent rejection prophylaxis for pancreas transplantation

Transplantation

Volumn 75, Issue 8, 2003, Pages 1301-1306

  Knight, Richard J ^a   Kerman, Ronald H ^a   Zela, Scott ^a   Podder, Hemangshu ^a   Van Buren, Charles T ^a   Katz, Stephen ^a   Kahan, Barry D ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CREATININE; CYCLOSPORIN A; GLUCOSE; HLA ANTIGEN; RAPAMYCIN; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY TITER; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONFERENCE PAPER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LENGTH OF STAY; MALE; PANCREAS TRANSPLANTATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; THROMBOSIS;

ADULT; ANTILYMPHOCYTE SERUM; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HERNIA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LIPIDS; MALE; MIDDLE AGED; PANCREAS; PANCREAS TRANSPLANTATION; PROSPECTIVE STUDIES; SIROLIMUS; SURGICAL WOUND INFECTION; T-LYMPHOCYTES;

EID: 0037469024     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000061768.98058.EC     Document Type: Conference Paper

References (10)

1. Gruessner AC, Sutherland DE. Analysis of United States (US) and non-US pancreas transplants reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of October 2001. In: Cecka JM, Terasaki PI, eds. Clinical Transplants 2001. Los Angeles, UCLA Immunogenetics Center 2002, pp 41-72.
2. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicenter study. The Rapamune US Study Group. Lancet 2000; 356: 194.
3. Macdonald AS. A worldwide, phase III, randomized, controlled safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271.
4. Hong JC, Kahan BD. A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft survival. Transplantation 2001; 71: 1320.
5. Macdonald AS, Kiberd B, Salazar A, et al. Rapamycin and low-dose tacrolimus in kidney-pancreas recipients: a 12-36 month follow-up [abstract]. Am J Transplant 2002; 2(suppl 3): 141.
6. Kaufman DB, Leventhal JR, Koffron AJ, et al. A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation. Transplantation 2002; 73: 169.
7. Benedetti E, Coady NT, Asolati M, et al. A prospective randomized clinical trial of perioperative treatment with octreotide in pancreas transplantation. Am J Surg 1998; 175: 14.
8. Morelon E, Stern M, Israel-Biët D, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001; 72: 787.
9. Knight RJ, Van Buren CT, Katz SM, et al. Induction immunosuppression for cadaveric renal transplantation utilizing sirolimus, basiliximab and delayed introduction of cyclosporine [abstract]. Am J Transplant 2001; 1(suppl 1): 277.
10. Seaman DS, Weigel KA, Siegel CT, et al. Adverse effects of sirolimus on wound healing in kidney transplantation [abstract]. Am J Transplant 2002; 2(suppl 3): 141.